(July 21, 2023, 11:08 AM EDT) -- ALEXANDRIA, Va. — The Patent Trial and Appeal Board on July 20 instituted inter partes review of a Regeneron Pharmaceuticals Inc. patent directed to a vascular endothelial growth factor (VEGF) antagonist, also known as “VEGF trap,” writing that a petitioner “has sufficiently shown error” by the U.S. Patent and Trademark Office (PTO) in its analysis of prior art....